RVTY Stock Analysis: Revvity | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 16.909m USD | 12M Return: 68.7% | US7140461093 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 323M
EPS Trend: 63.1%
Qual. Beats: 3
Rev. Trend: 79.9%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Revvity, Inc. (NYSE: RVTY) is a U.S.-based health sciences company headquartered in Waltham, Massachusetts, that provides instruments, reagents, software, and services to pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, and government agencies. The company was founded in 1937 and operated as PerkinElmer, Inc. before adopting the Revvity name in April 2023.
The business operates across two primary end markets: diagnostics and life sciences. In diagnostics, Revvity supplies testing and screening products for conditions such as pregnancy, Down syndrome, hypothyroidism, muscular dystrophy, infertility, and infectious diseases. In life sciences, it develops genomic workflow tools, including next-generation DNA sequencing and protein-coupled receptor technologies, used in oncology, immunodiagnostics, and drug discovery applications.
Revvity sits within the Life Sciences Tools & Services sub-industry of the Health Care sector, a segment whose business model is typically anchored by a mix of capital equipment sales and recurring revenue from consumables, kits, and software subscriptions. The company markets its offerings under a wide range of brand names, including AutoDELFIA, EUROIMMUN, Vanadis, ViaCord, AlphaLISA, BioLegend, and Dharmacon.
- Biotech R&D demand lifts Life Sciences segment revenue
- Diagnostics margins pressured by lower newborn screening volumes
- China sales face geopolitical and tariff headwinds
| Net Income: 237.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.58 > 1.0 |
| NWC/Revenue: 35.08% < 20% (prev 55.90%; Δ -20.82% < -1%) |
| CFO/TA 0.05 > 3% & CFO 629.0m > Net Income 237.6m |
| Net Debt (2.45b) to EBITDA (767.0m): 3.20 < 3 |
| Current Ratio: 1.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (111.7m) vs 12m ago -4.93% < -2% |
| Gross Margin: 52.11% > 18% (prev 54.05%; Δ -1.94% > 0.5%) |
| Asset Turnover: 23.86% > 50% (prev 22.64%; Δ 1.22% > 0%) |
| Interest Coverage Ratio: 3.77 > 6 (EBIT TTM 354.8m / Interest Expense TTM 94.0m) |
| A: 0.08 (Total Current Assets 2.30b - Total Current Liabilities 1.28b) / Total Assets 12.0b |
| B: 0.51 (Retained Earnings 6.13b / Total Assets 12.0b) |
| C: 0.03 (EBIT TTM 354.8m / Avg Total Assets 12.2b) |
| D: 1.50 (Book Value of Equity 7.23b / Total Liabilities 4.82b) |
| Altman-Z'' = 3.99 = AA |
| DSRI: 1.03 (Receivables 709.2m/661.1m, Revenue 2.91b/2.80b) |
| GMI: 1.04 (GM 54.05% / 52.11%) |
| AQI: 0.99 (AQ_t 0.76 / AQ_t-1 0.76) |
| SGI: 1.04 (Revenue 2.91b / 2.80b) |
| TATA: -0.03 (NI 237.6m - CFO 629.0m) / TA 12.0b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at USD 154.18 with a total of 1,224,272 shares traded. Over the past week, the price has changed by +1.75%, over one month by +24.49%, over three months by +36.59% and over the past year by +68.67%.
Current recommended Stop Loss: 143.40 (which is 7% or 1.8 ATR below the current price).
Revvity has received a consensus analysts rating of 3.53. Therefore, it is recommended to hold RVTY.
- StrongBuy: 5
- Buy: 0
- Hold: 11
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 130.3 | -15.5% |
P/E Trailing = 72.851
P/E Forward = 24.1546
P/S = 5.8069
P/B = 2.1937
P/EG = 0.7337
Revenue TTM = 2.91b USD
EBIT TTM = 354.8m USD
EBITDA TTM = 767.0m USD
Long Term Debt = 2.63b USD (from longTermDebt, last quarter)
Short Term Debt = 572.2m USD (from shortTermDebt, last quarter)
Debt = 3.48b USD (from shortLongTermDebtTotal, last quarter) + Leases 136.3m
Net Debt = 2.45b USD (calculated: Debt 3.48b - CCE 1.02b)
Enterprise Value = 19.4b USD (16.9b + Debt 3.48b - CCE 1.02b)
Interest Coverage Ratio = 3.77 (Ebit TTM 354.8m / Interest Expense TTM 94.0m)
EV/FCF = 34.62x (Enterprise Value 19.4b / FCF TTM 559.3m)
FCF Yield = 2.89% (FCF TTM 559.3m / Enterprise Value 19.4b)
FCF Margin = 19.21% (FCF TTM 559.3m / Revenue TTM 2.91b)
Net Margin = 8.16% (Net Income TTM 237.6m / Revenue TTM 2.91b)
Gross Margin = 52.11% ((Revenue TTM 2.91b - Cost of Revenue TTM 1.39b) / Revenue TTM)
Gross Margin QoQ = 57.13% (prev 54.51%)
Tobins Q-Ratio = 1.61 (Enterprise Value 19.4b / Total Assets 12.0b)
Interest Expense / Debt = 2.70% (Interest Expense 94.0m / Debt 3.48b)
Taxrate = 7.98% (20.8m / 260.8m)
NOPAT = 326.5m (EBIT 354.8m * (1 - 7.98%))
Current Ratio = 1.80 (Total Current Assets 2.30b / Total Current Liabilities 1.28b)
Debt / Equity = 0.48 (Debt 3.48b / totalStockholderEquity, last quarter 7.23b)
Debt / EBITDA = 3.20 (Net Debt 2.45b / EBITDA 767.0m)
Debt / FCF = 4.39 (Net Debt 2.45b / FCF TTM 559.3m)
Total Stockholder Equity = 7.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.95% (Net Income 237.6m / Total Assets 12.0b)
RoE = 3.27% (Net Income TTM 237.6m / Total Stockholder Equity 7.26b)
RoCE = 3.59% (EBIT 354.8m / Capital Employed (Equity 7.26b + L.T.Debt 2.63b))
RoIC = 2.92% (NOPAT 326.5m / Invested Capital 11.2b)
WACC = 7.96% (E(16.9b)/V(20.4b) * Re(9.09%) + D(3.48b)/V(20.4b) * Rd(2.70%) * (1-Tc(0.08)))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.08 | Cagr: -4.36%
[DCF] Terminal Value 76.80% ; FCFF base≈536.8m ; Y1≈588.9m ; Y5≈744.6m
[DCF] Fair Price = 79.96 (EV 11.4b - Net Debt 2.45b = Equity 8.92b / Shares 111.6m; r=8.35% [WACC [floored]]; 5y FCF grow 11.21% → 2.50% )
EPS Correlation: 63.11 | EPS CAGR: 3.30% | SUE: 4.0 | # QB: 3
Revenue Correlation: 79.88 | Revenue CAGR: 2.17% | SUE: 4.0 | # QB: 3
EPS current Quarter (2026-09-30): EPS=1.29 | Chg30d=+0.29% | Revisions=-80% | Analysts=14
EPS current Year (2026-12-31): EPS=5.35 | Chg30d=-0.02% | Revisions=+77% | GrowthEPS=+5.7% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=5.89 | Chg30d=+0.03% | Revisions=+44% | GrowthEPS=+10.2% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: +13% (up=20, down=15)